NASDAQ:KMPH - KemPharm Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding KemPharm Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.37 +0.01 (+2.78 %) (As of 01/27/2020 02:41 PM ET) Add Compare Today's Range$0.37Now: $0.37▼$0.3950-Day Range$0.28MA: $0.42▼$0.7652-Week Range$0.26Now: $0.37▼$2.82Volume709,818 shsAverage Volume2.09 million shsMarket Capitalization$12.28 millionP/E RatioN/ADividend YieldN/ABeta1.26 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMPH Previous Symbol CUSIPN/A CIK1434647 Webhttp://www.kempharm.com/ Phone321-939-3416Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.52) per share Price / Book-0.15Profitability EPS (Most Recent Fiscal Year)($2.49) Net Income$-56,470,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-138.01%Miscellaneous Employees33 Outstanding Shares33,220,000Market Cap$12.28 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive KMPH News and Ratings via Email Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KMPH Rates by TradingView KemPharm (NASDAQ:KMPH) Frequently Asked Questions What is KemPharm's stock symbol? KemPharm trades on the NASDAQ under the ticker symbol "KMPH." How were KemPharm's earnings last quarter? KemPharm Inc (NASDAQ:KMPH) announced its quarterly earnings data on Thursday, November, 14th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.34. The specialty pharmaceutical company had revenue of $11.46 million for the quarter. View KemPharm's Earnings History. When is KemPharm's next earnings date? KemPharm is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for KemPharm. What price target have analysts set for KMPH? 3 analysts have issued twelve-month price objectives for KemPharm's stock. Their forecasts range from $1.05 to $3.00. On average, they expect KemPharm's share price to reach $2.18 in the next twelve months. This suggests a possible upside of 490.4% from the stock's current price. View Analyst Price Targets for KemPharm. What is the consensus analysts' recommendation for KemPharm? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KemPharm. What are Wall Street analysts saying about KemPharm stock? Here are some recent quotes from research analysts about KemPharm stock: 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (11/23/2019) 2. HC Wainwright analysts commented, "Our $3 12-month target is based on a 65% probability of success adjusted DCF including profit split from Apadaz—approved and partnered prodrug of IR hydrocodone, pilot launching in 2H19—and royalties and milestones from KP415 from partner GPC. We project peak $23M KP415 revenue to KMPH at 100% gross margins. Both have IP into the 2030s. We see most near-term revenue solely from milestones, before product royalties and profit share accelerate in 2022-2023, with KemPharm sustainable profitability in 2023." (9/5/2019) Has KemPharm been receiving favorable news coverage? Media stories about KMPH stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. KemPharm earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for KemPharm. Who are some of KemPharm's key competitors? Some companies that are related to KemPharm include Merrimack Pharmaceuticals (MACK), Humanigen (HGEN), Leap Therapeutics (LPTX), Forward Pharma A/S (FWP), Adamis Pharmaceuticals (ADMP), Moleculin Biotech (MBRX), Acer Therapeutics (ACER), IntelGenx Technologies (IGXT), Q BioMed (QBIO), PLx Pharma (PLXP), Zafgen (ZFGN), Medicure (MCUJF), Pharmaxis (PXSLY), Jaguar Health (JAGX) and Iterum Therapeutics (ITRM). What other stocks do shareholders of KemPharm own? Based on aggregate information from My MarketBeat watchlists, some companies that other KemPharm investors own include Sorrento Therapeutics (SRNE), Tandem Diabetes Care (TNDM), Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE). Who are KemPharm's key executives? KemPharm's management team includes the folowing people: Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)Dr. Sven Guenther, Exec. VP of R&D (Age 47)Mr. Gordon K. Johnson, Chief Bus. Officer (Age 67)Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47) When did KemPharm IPO? (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. Who are KemPharm's major shareholders? KemPharm's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.37%). Company insiders that own KemPharm stock include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Institutional Ownership Trends for KemPharm. Which institutional investors are buying KemPharm stock? KMPH stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Insider Buying and Selling for KemPharm. How do I buy shares of KemPharm? Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is KemPharm's stock price today? One share of KMPH stock can currently be purchased for approximately $0.37. How big of a company is KemPharm? KemPharm has a market capitalization of $12.28 million. The specialty pharmaceutical company earns $-56,470,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. KemPharm employs 33 workers across the globe.View Additional Information About KemPharm. What is KemPharm's official website? The official website for KemPharm is http://www.kempharm.com/. How can I contact KemPharm? KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected] MarketBeat Community Rating for KemPharm (NASDAQ KMPH)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 313 (Vote Outperform)Underperform Votes: 216 (Vote Underperform)Total Votes: 529MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is a Call Option?
